Effects of interleukin-2 in immunostimulation and immunosuppression

Historically, interleukin-2 (IL-2) was first described as an immunostimulatory factor that supports the expansion of activated effector T cells. A layer of sophistication arose when regulatory CD4+ T lymphocytes (Tregs) were shown to require IL-2 for their development, homeostasis, and immunosuppres...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of experimental medicine Vol. 217; no. 1
Main Authors Pol, Jonathan G, Caudana, Pamela, Paillet, Juliette, Piaggio, Eliane, Kroemer, Guido
Format Journal Article
LanguageEnglish
Published United States Rockefeller University Press 06.01.2020
SeriesCytokines Focus
Subjects
Reviews
Online AccessGet full text

Cover

More Information
Summary:Historically, interleukin-2 (IL-2) was first described as an immunostimulatory factor that supports the expansion of activated effector T cells. A layer of sophistication arose when regulatory CD4+ T lymphocytes (Tregs) were shown to require IL-2 for their development, homeostasis, and immunosuppressive functions. Fundamental distinctions in the nature and spatiotemporal expression patterns of IL-2 receptor subunits on naive/memory/effector T cells versus Tregs are now being exploited to manipulate the immunomodulatory effects of IL-2 for therapeutic purposes. Although high-dose IL-2 administration has yielded discrete clinical responses, low-dose IL-2 as well as innovative strategies based on IL-2 derivatives, including "muteins," immunocomplexes, and immunocytokines, are being explored to therapeutically enhance or inhibit the immune response.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0022-1007
1540-9538
DOI:10.1084/jem.20191247